VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 87 filers reported holding VAXCYTE INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $29,714,662 | -51.4% | 582,869 | -52.4% | 0.02% | -50.0% |
| Q2 2023 | $61,130,156 | +124060.0% | 1,224,072 | -6.8% | 0.03% | +7.1% |
| Q1 2023 | $49,235 | -15.8% | 1,313,642 | +7.7% | 0.03% | -12.5% |
| Q4 2022 | $58,475 | -99.7% | 1,219,491 | +55.1% | 0.03% | +190.9% |
| Q3 2022 | $18,872,000 | +53.2% | 786,322 | +38.9% | 0.01% | +37.5% |
| Q2 2022 | $12,319,000 | +94.2% | 566,116 | +115.5% | 0.01% | +166.7% |
| Q1 2022 | $6,345,000 | -6.9% | 262,720 | -8.2% | 0.00% | 0.0% |
| Q4 2021 | $6,812,000 | -4.5% | 286,323 | +1.8% | 0.00% | -25.0% |
| Q3 2021 | $7,136,000 | +0.5% | 281,284 | -10.9% | 0.00% | 0.0% |
| Q2 2021 | $7,104,000 | +1.8% | 315,613 | -10.7% | 0.00% | -20.0% |
| Q1 2021 | $6,981,000 | -38.3% | 353,454 | -17.0% | 0.01% | -37.5% |
| Q4 2020 | $11,314,000 | +139.5% | 425,824 | +345.1% | 0.01% | +33.3% |
| Q3 2020 | $4,724,000 | -82.8% | 95,660 | -89.0% | 0.01% | -84.2% |
| Q2 2020 | $27,448,000 | – | 868,318 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Abingworth LLP | 4,168,718 | $90,711,000 | 29.04% |
| Medicxi Ventures Management (Jersey) Ltd | 3,774,956 | $82,142,000 | 17.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 832,166 | $18,108,000 | 9.12% |
| GREAT POINT PARTNERS LLC | 985,153 | $21,437,000 | 5.14% |
| Kynam Capital Management, LP | 723,781 | $15,749,000 | 4.02% |
| Ghost Tree Capital, LLC | 325,000 | $7,072,000 | 3.68% |
| Frazier Life Sciences Management, L.P. | 1,787,405 | $38,894,000 | 3.67% |
| RA Capital Management | 4,581,203 | $99,687,000 | 2.66% |
| Opaleye Management Inc. | 190,000 | $4,134,000 | 1.86% |
| Soleus Capital Management, L.P. | 370,650 | $8,065,000 | 1.26% |